Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prais

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
European Journal of Pediatrics|November 27, 2025
Risk factors associated with severe RSV disease among hospitalized children in the second year of life: a multicenter studyKeren Armoni Domany, Inbal Golan-Tripto, Nitzan Burrack, et al.
Pediatric Pulmonology|March 5, 2025
Respiratory Syncytial Virus Burden in Premature Infants: The Role of Season With and Without RSV Immunoprophylaxis in a Multicenter StudyKeren Armoni Domany, Avigdor Mandelberg, Nitzan Burrack, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 18, 2023
The new face of cystic fibrosis in the era of population genetic carrier screeningMiri Dotan, Hannah Blau, Amihood Singer, et al.
Pediatric Pulmonology|October 23, 2025
Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross-Sectional Study in IsraelLior Tsviban, Nofar Amitai, Hagit Levine, et al.
The New England Journal of Medicine|October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesJane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.
Molecular Genetics & Genomic Medicine|May 27, 2017
Nationwide genetic analysis for molecularly unresolved cystic fibrosis patients in a multiethnic society: implications for preconception carrier screeningDoron M Behar, Ori Inbar, Michal Shteinberg, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.
The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trialsClaire Keating, Lael M Yonker, François Vermeulen, et al.
Respiratory Medicine|May 12, 2024
Maternal and fetal outcomes in multiparous women with Cystic FibrosisMalena Cohen-Cymberknoh, Maya Ariel Dabby, Bar Gindi Reiss, et al.
Respiratory Medicine|October 4, 2016
Primary ciliary dyskinesia in Israel: Prevalence, clinical features, current diagnosis and management practicesRevital Abitbul, Israel Amirav, Hannah Blau, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
European Journal of Pediatrics|November 27, 2025
Risk factors associated with severe RSV disease among hospitalized children in the second year of life: a multicenter studyKeren Armoni Domany, Inbal Golan-Tripto, Nitzan Burrack, et al.
Pediatric Pulmonology|March 5, 2025
Respiratory Syncytial Virus Burden in Premature Infants: The Role of Season With and Without RSV Immunoprophylaxis in a Multicenter StudyKeren Armoni Domany, Avigdor Mandelberg, Nitzan Burrack, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 18, 2023
The new face of cystic fibrosis in the era of population genetic carrier screeningMiri Dotan, Hannah Blau, Amihood Singer, et al.
Pediatric Pulmonology|October 23, 2025
Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross-Sectional Study in IsraelLior Tsviban, Nofar Amitai, Hagit Levine, et al.
The New England Journal of Medicine|October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesJane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.
Molecular Genetics & Genomic Medicine|May 27, 2017
Nationwide genetic analysis for molecularly unresolved cystic fibrosis patients in a multiethnic society: implications for preconception carrier screeningDoron M Behar, Ori Inbar, Michal Shteinberg, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.
The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trialsClaire Keating, Lael M Yonker, François Vermeulen, et al.
Respiratory Medicine|May 12, 2024
Maternal and fetal outcomes in multiparous women with Cystic FibrosisMalena Cohen-Cymberknoh, Maya Ariel Dabby, Bar Gindi Reiss, et al.
Respiratory Medicine|October 4, 2016
Primary ciliary dyskinesia in Israel: Prevalence, clinical features, current diagnosis and management practicesRevital Abitbul, Israel Amirav, Hannah Blau, et al.
Pageof 17